Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SAR studies demonstrated amide substituted (Z)-β-enaminones as precise PI3K inhibitors to treat breast cancer.
|
30515835 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovery and synthesis of 2-amino-1-methyl-1H-imidazol-4(5H)-ones as GPCR ligands; an approach to develop breast cancer drugs via GPCR associated PAR1 and PI3Kinase inhibition mechanism.
|
30822721 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAR2 and G-CSF were significantly more expressed in metastatic (4T1 and MDA-MB-231) as compared to non-metastatic (67NR and MCF7) breast cancer cell lines.
|
30172372 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, tryptase activated EPCs via PAR-2-mediated AKT and ERK signaling pathway activation, thereby enhancing angiogenesis in breast cancer.
|
30008831 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
|
28622580 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that Twist overexpression increased expression of PAR1, an upstream regulator of the Hippo pathway; PAR1 promotes invasion, migration, and CSC-like properties in breast cancer by activating the transcriptional co-activator TAZ.
|
27094683 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PAR2 belongs to the superfamily of GPCRs and is an important target for breast cancer.
|
25386994 |
2015 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NF-κB contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier in vitro.
|
26513020 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show signal-binding motifs in PAR1&2 that are critical for breast cancer growth.
|
26600192 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammalian protease-activated-receptor-1 and -2 (PAR1 and PAR2) are activated by proteases found in the flexible microenvironment of a tumor and play a central role in breast cancer.
|
24177339 |
2014 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
|
24398324 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis.
|
24009311 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast cancer growth is suppressed by inhibition of TF-mediated PAR2 signaling, and deficiency in PAR2 delays spontaneous breast cancer development in mice.
|
23287882 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our observation that PAR1 expression and signal transduction are modulated by progesterone provides new insight into how the progestin component in hormone therapies increases the risk of breast cancer in postmenopausal women.
|
22593082 |
2012 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, IL-1β and TNF-α induced ABCG2 and PXR expression and NF-κB activity in some breast cancer and normal cell lines.
|
22750628 |
2012 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study suggested the protective effect of the allele D at -506 locus of PAR1 gene on the recurrence of breast cancer.
|
21822552 |
2012 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
None of the 31 analyzed transporter and PXR polymorphisms showed an association with breast cancer risk or tumor characteristics.
|
20635135 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging evidence has implicated G protein-coupled receptors, such as CXCR4 and PAR2, in breast cancer progression and the development of metastatic breast cancer.
|
21318602 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, interleukin-1β and tumor necrosis factor-α induced ABCG2 and PXR mRNAs in the MCF7 breast cancer cell line; no significant changes on expression of the same genes in MCF7/MX cells were observed.
|
20846001 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results begin to delineate the mechanism by which thrombin activates a PAR-1/PAR-2 complex to induce PAI-1 expression in the 4T1 murine breast cancer cell line.
|
21799402 |
2011 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since many breast cancer preventive and therapeutic compounds are SXR activators, we hypothesized that some beneficial effects of these compounds are mediated through SXR.
|
19123943 |
2009 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest PAR1 overexpression may be involved in the development of metastases in breast cancer patient and is associated with undifferentiated cellular progression of the tumor.
|
19538737 |
2009 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Regulation of drug resistance by human pregnane X receptor in breast cancer.
|
19746521 |
2009 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the expression of SXR in breast cancer cells may alter the ER signaling, which may play crucial role for growth and differentiation of breast cancer cells.
|
19011999 |
2008 |